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Abstract: Fluorination of 13-epimeric estrones and their 17-deoxy counterparts was performed 
with Selectfluor as the reagent. In acetonitrile or trifluoroacetic acid (TFA), 
10β-fluoroestra-1,4-dien-3-ones were formed exclusively. Mechanistic investigations suggest that 
fluorinations occurred via SET in acetonitrile, but another mechanism was operative in TFA. 
Simultaneous application of N-chlorosuccinimide (NCS) and Selectfluor in TFA led to a 1.3:1 
mixture of 10β-fluoroestra-1,4-dien-3-one and 10β-chloroestra-1,4-dien-3-one as the main products. 
The potential inhibitory action of the 10-fluoro- or 10-chloroestra-1,4-dien-3-one products on 
human aromatase was investigated via in vitro radiosubstrate incubation. The classical estrane 
conformation with trans ring anellations and a 13β-methyl group seems to be crucial for the 
inhibition of the enzyme, while test compounds bearing the 13β-methyl group exclusively 
displayed potent inhibitory action with submicromolar or micromolar IC50 values. Concerning 
molecular level explanation of biological activity or inactivity, computational simulations were 
performed. Docking studies reinforced that besides the well-known Met374 H-bond connection, 
the stereocenter in the 13 position has an important role in the binding affinity. The configuration 
inversion at C-13 results in weaker binding of 13α-estrone derivatives to the aromatase enzyme. 
Keywords: 13α-estrone; Selectfluor; aromatase; docking; TEMPO; single electron transfer 
 
1. Introduction 
Aromatase is responsible for the aromatization of androgens to estrogens [1]. The 
overproduction of estrogens stimulates the proliferation of estrogen-sensitive cells, leading to 
estrogen-dependent cancers. The proliferative action of estrogens might be prevented by inhibition 
of the aromatase enzyme [2]. Aromatase inhibitors can be categorized by their mechanism of action. 
Type I inhibitors are known as steroidal, and type II as nonsteroidal inhibitors [1]. The type I 
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compounds are usually related to substrates of the enzyme and they are either competitive 
inhibitors or act as suicide inhibitors [3,4]. Formestane and Atamestane belong to the type I group. 
Formestane is considered to be the structural analog of androstenedione and it was the first member 
to enter clinical trials. Despite their high inhibitory potency, both agents have unfavorable 
metabolism and poor oral bioavailability. These disadvantages led to the discovery of a more potent 
compound, named Exemestane, acting both as a competitive and irreversible inhibitor. 
Additionally, it is efficient in metastatic breast cancer after the failure of selective estrogen receptor 
modulators (SERMs) [3]. This agent has substantial advantages over the nonsteroidal aromatase 
inhibitors. Thanks to the mentioned benefits of Exemestane, subsequent novel therapeutics were 
developed using a steroidal backbone as the scaffold. Nowadays, there is a high need for new 
aromatase inhibitory agents, because drawbacks as androgenic effect or metabolism by other CYP 
enzymes could still not be avoided. 
Attempts have been made in recent decades to decrease the side-effects of the known inhibitors 
by performing minor structural modifications on the sterane skeleton [1]. Certain modifications 
were based on retaining the ring A dienone and androstane structure. One of the most explored 
groups of aromatase inhibitors is the 19-substituted androstane class. Marcotte and Robinson 
published work on C-19-modified androsta-4-en-3-one derivatives [5]. The 19-monofluoro and its 
difluoro counterpart displayed aromatase inhibitory activity with a Ki value of 1 µM. These 
literature data indicate that both the presence of an enone moiety in ring A and the fluorinated 
β-oriented angular 10-methyl group are advantageous structural elements concerning aromatase 
inhibition. Halogenation was also performed on the androsta-1,4-diene-3,17-dione skeleton [6]. 
Chlorine was introduced onto C-19, and the resulting compound displayed potent inhibitory 
activity with a 1-micromolar IC50 value. Not only ring A, but also ring D modifications have been 
performed. Sherwin et al. published the comparison of the inhibitory data of 17-oxo and the parent 
17-deoxy androsta-1,4-dien-3-one compounds [7]. They concluded that the removal of the 17-oxo 
function causes only minor differences in the aromatase inhibitory potential of 
androsta-1,4-dien-3-ones. 
Incorporation of fluorine into a biomolecule may lead to beneficial biological properties [8]. The 
C–F bond participates in attractive interactions with hydrogen bond donors, certain polar functional 
groups, and hydrophobic moieties. This is due to the large C–F bond polarization, which originates 
from the high electronegativity of fluorine. Fluorinated molecules usually have high binding affinity 
to certain proteins and increased metabolic stability. Recently, a class of stable and crystalline N–F 
fluorinating agents has been developed. 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) (Selectfluor (2), F-TEDA-BF4) belongs to the latter group and behaves as a 
selective fluorinating agent with high functional group tolerance [9–12]. Selectfluor is exceptionally 
stable and may serve as a fluoronium cation source. It is soluble in a few polar solvents, namely, 
acetonitrile, N,N-dimethylformamide (DMF), nitromethane and water. Literature data reveal that 
the type of fluorination of aromatic molecules with Selectfluor strongly depends on both the nature 
and the position of the aromatic ring substituents as well as on reaction conditions. Pravst et al. 
performed fluorinations of p-substituted phenols (1) using Selectfluor (2) as fluorinating agent in 
acetonitrile or methanol under different conditions (Scheme 1) [13]. The greatest solvent-dependent 
difference in product distributions was observed starting from 4-methylphenol (1a), where products 
3a and 4a were formed in a ratio of nearly 2:1 in acetonitrile (reflux, 2 h), but in 3a:4a = 0:1 in 
methanol (reflux, 2 h). Concerning the largest substituent in the starting compound (1d), no dienone 
(3d) was formed, and the 4d:5d = 88:12 ratio was the same, independent of the solvent used. 
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Scheme 1. Fluorination of p-substituted phenols (1) with Selectfluor (2). 
According to the literature, 17β-estradiol (6), estrone (7) or their certain ring D-substituted 
derivatives can be converted to 10β-fluoroestra-1,4-dien-3-one analogues (8 and 9) with Selectfluor 
in different solvents (acetonitrile or bmimBF4:MeOH = 1:1, H2O) or under solvent-free conditions 
(Scheme 2) [14–17]. Independent of the nature of the solvent, all reactions resulted in dienones 8 and 
9 as main products. ortho-substituted derivatives were observed only in trace amounts. Bogautdinov 
et al. reported the stereoselective fluorination of the 8α-epimer of 17β-estradiol (10) in the 1:1 
mixture of bmimBF4 and methanol (Scheme 2) [14]. They proved that the reaction leads to 10-fluoro 
derivative 11 as the main product with α-orientation of fluorine. It was established that the 
configuration of C-8 influences the chirality of the newly formed C-10 stereogenic center. 
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Scheme 2. Fluorination of estrone derivatives (6, 7 or 10) with Selectfluor (2). 
Natural estrone derivatives (6 and 7) exhibit a relatively rigid molecular framework with 
well-defined distances between the two oxygen functionalities, which might be essential in the 
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binding of the biomolecule to its receptors or enzymes. In contrast to natural 
13β-estra-1,3,5(10)-trienes, 13α derivatives possess a cis-junction of the C and D rings, a 
quasi-equatorial 13α-methyl group and a ring D that is directed to the β-side (Figure 1) [18,19]. 
13α-Estrone derivatives exist either in a usual conformation (with chair ring C) or in an unusual 
steroid conformation (with a twist-boat ring C). The conformational changes lead to a complete loss 
of estrogenic activity in estrone (7) or 17α/β-estradiols with inverted configuration at C-13 [20]. Thus, 
the inversion of certain chiral carbon atoms of the estrane core may lead to completely different 
biological behavior. Accordingly, 13α-estrone (12, Figure 1) may serve as a suitable scaffold for the 
design of biologically active estrane derivatives lacking estrogenic behavior. 
Here, we aimed to perform fluorination of hormonally inactive 13α-estrone 12 in order to 
obtain novel potential steroidal aromatase inhibitors bearing the 1,4-dien-3-one structural moiety in 
ring A. We aimed to examine the chemo- and stereoselectivity of the fluorination with Selectfluor (2) 
under various conditions. The investigation of the reaction mechanism was planned by adding a 
radical scavenger to the reaction mixture. Another substrate, 17-deoxy-13α-estrone 14, was also 
subjected to these transformations with the aim of investigating the influence of the lack of the 
17-oxo group on the scope of the reactions. Comparative studies in the 13β- and 13α-estrone series 
(from starting compounds 7 and 12–14) have also been planned. The determination of the potential 
inhibitory action of the 10-fluorinated estra-1,4-dien-3-one products (9, 17, 20, and 21; Scheme 3) on 
human aromatase enzyme was planned via in vitro radiosubstrate incubation. Finally, having 
obtained a molecular-level insight into the binding properties of the 10-halo-13-epimeric estrane 
derivatives (9, 17, and 20–22) structure-activity information was collected and computational 
investigations were performed. These docking simulations helped to understand the more profound 
consequence of our chemical modifications concerning the ligand–receptor interaction. 
 
Figure 1. The structure of 13-epimeric estrones (7 and 12) and their 17-deoxy counterparts (13 and 
14). 
2. Results and Discussion 
2.1. Chemistry 
Fluorinations of 13-epimeric estrones (7 and 12) with Selectfluor (2) were performed in different 
solvents (Scheme 3). Based on literature results, two solvents were selected: acetonitrile and 
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methanol [12]. Reactions were performed at room temperature or at 80 °C. First, chemo- and 
regioselectivities were studied in acetonitrile (Scheme 3, Table 1, Entries 1–3 and 7–9). Stirring of the 
reaction mixtures at room temperature led to 10β-fluorinated derivatives (9 and 17) solely, 
independent of the orientation of the angular methyl group (Table 1, Entries 1 and 7). Thus, 
10β-fluoroestra-1,4-dien-3-ones (9 and 17) were formed in stereo- and chemoselective manners. 
Aromatic electrophilic substitutions at the ortho-positions (at C-2 or at C-4) did not occur. When 
fluorinations were carried out at 80 °C in acetonitrile, the same 10-fluoro products (9 or 17) were 
formed, but the reaction was complete within 1 h (Table 1, Entries 2 and 8). Our results are not 
consistent with those obtained for monosubstituted phenols [13], but they show good 
correspondence with chemoselectivities obtained earlier for fluorinations of estrone derivatives with 
Selectfluor [14–17]. In methanol, however, ortho-fluorinations also occurred (15–16%: 15:16 =1:0.9 or 
18:19 =1:1.5) at both reaction temperatures (Table 1, Entries 4,5,10 and 11). 
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Scheme 3. Fluorinations of estrone (7) and 13α-estrone (12) with Selectfluor (2). 
In order to investigate the influence of minor structural modifications of the steroidal scaffold 
on the outcome of fluorinations, not only the 17-oxo compound, but also their 17-deoxy counterparts 
(13 and 14) were subjected to fluorinations in acetonitrile using 2 as the reagent (Scheme 4, Table 1, 
Entries 13, 14). As expected, the reactions proceeded chemo- and stereoselectively, resulting in 
10β-fluoro-17-deoxy-estra-1,4-dien-3-ones (20 and 21) in both the 13β- and 13α-estrone series. It can 
be stated that the presence or lack of the 17-oxo function does not affect the outcome of these 
fluorination reactions. 
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Scheme 4. Fluorinations of 17-deoxyestrone (13) and 17-deoxy-13α-estrone (14) with Selectfluor (2). 
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Table 1. Fluorinations of estrone (7), 13α-estrone (12), 17-deoxyestrone (13) or 17-deoxy-13α-estrone 
(14) with Selectfluor (2). 
Entry Substrate Solvent Temperature Reaction Time Product Yield (%) 
1 7 acetonitrile rt 24 h 9 95 
2 7 acetonitrile 80 °C 1 h 9 97 
3 a 7 acetonitrile rt 24 h 9 3 
4 7 methanol rt 24 h 9 + (15 + 16) b 76 + (16) 
5 7 methanol reflux 1 h 9 + (15 + 16) 78 + (15) 
6 a 7 methanol rt 24 h 9 2 
7 12 acetonitrile rt 24 h 17 97 
8 12 acetonitrile 80 °C 1 h 17 98 
9 a 12 acetonitrile rt 24 h 17 4 
10 12 methanol rt 24 h 17 + (18 + 19) c 71 + (12) 
11 12 methanol reflux 1 h 17 + (18 + 19) 73 + (13) 
12 a 12 methanol rt 24 h 17 94 
13 13 acetonitrile rt 24 h 20 94 
14 14 acetonitrile rt 24 h 21 92 
a 2 equiv. of 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO); b Ratio: 15:16 = 1:0.9; c Ratio: 18:19 = 1:1.5. 
According to the literature, the reaction mechanisms of fluorination reactions with Selectfluor 
(2) and other N–F fluorinating agents might be highly sensitive to the applied reaction conditions 
[21–23]. Different results have been observed with the same radical probe in different solvents. 
However, the ability of Selectfluor for homolytic cleavage of its N–F bond has recently been proved 
by Zhang et al., who detected the adduct of TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy) and the 
fluorine radical by LC-MS and F-NMR [24]. Based on these literature results, we investigated the 
mechanism of fluorination in acetonitrile and methanol by adding a radical scavenger to the reaction 
mixture (Scheme 5, Table 1, Entries 3, 6, 9, 12). Addition of 2 equiv. of TEMPO resulted in almost 
complete inhibition of fluorination, and only a trace of the desired 10-fluoro derivative (9) was 
formed. This indicates that fluorination presumably occurred via SET. Based on literature evidence 
[21,24] and our results, we assume that the homolytic cleavage of the N–F bond results in a fluorine 
radical and cationic nitrogen radical 2A. The latter is protonated and intermediate 7R is formed. 
Subsequent spin delocalization results in intermediate 7RD. The driving force of this delocalization 
is the formation of a more stable tertiary radical. The attack of the fluorine radical on C-10 results in 
the desired 10-fluoro derivative 9. 
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Scheme 5. Proposed mechanism of fluorination of estrone (7) with Selectfluor (2) in acetonitrile or 
methanol. 
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One substrate, namely 13β-estrone 7, was chosen for further derivatization. Chlorination of 
compound 7 was performed using N-chlorosuccinimide (NCS) as a reagent in acetonitrile and a 
catalytic amount of trifluoroacetic acid (TFA) (Scheme 6). Stirring the reaction mixture at rt for 24 h 
resulted in 2- and 4-chloro derivatives with retained aromaticity of ring A (23 and 24; Table 2, Entry 
1). Heating the reaction mixture at 80 °C afforded the same product mixture with a much shorter 
reaction time of only 1 h (Table 2, Entry 2). Exchanging acetonitrile for TFA, ortho-chlorination was 
suppressed and 10-chloro dienone 22 became the main product (Table 2, Entries 3,4). The outcome of 
the reaction could not be influenced by adding TEMPO to the reaction mixture (Table 2, Entry 5). 
Based on the above-mentioned interesting results, model compound 7 was subjected to fluorination 
with Selectfluor, but acetonitrile used formerly was exchanged for TFA as the solvent. Fluorination 
occurred solely at C-10 (Table 2, Entries 6, 7). The formation of compound 9 could not be avoided by 
adding TEMPO to the reaction mixture (Table 2, Entry 8). In further experiments, the two 
halogenating agents (Selectfluor and NCS) were used together. In acetonitrile, fluorination occurred 
at C-10 together with ortho-chlorinated products 23 and 24 (Table 2, Entry 9). This ratio was retained 
by heating the reaction mixture at 80 °C for 1 h, but the starting compound was consumed earlier 
(Table 2, Entry 10). The two halogenating agents were also simultaneously used in TFA. In this 
process, the 10-fluoro and 10-chloro compounds (9 and 22) appeared to be the main products (Table 
2, Entry 11). Heating shortened the reaction time, but it did not affect the product ratio (Table 2, 
Entry 12). TEMPO did not affect the outcome of this reaction either (Table 2, Entry 13). 
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Scheme 6. Reaction of estrone (7) with Selectfluor (2) and/or NCS. 
Table 2. Effect of the reaction conditions on the fluorination and/or chlorination of compound 7 
Entry Substrate NCS and or Selectfluor (1.1 equiv.) Solvent Temp. Reaction Time 
Yield Products  
9 + 22 + 23 + 24 (%) 
1 a 7 NCS acetonitrile rt 24 h 0 + 0 + 30 + 45 
2 a 7 NCS acetonitrile 80 °C 1 h 0 + 0 + 30 + 45 
3 7 NCS TFA rt 24 h 0 + 55 + 10 + 20 
4 7 NCS TFA 80 °C 1 h 0 + 55 + 10 + 20 
5 b 7 NCS TFA 80 °C 1 h 0 + 54 + 11 + 21 
6 7 Selectfluor TFA rt 24 h 96 + 0 + 0 + 0 
7 7 Selectfluor TFA 80 °C 1 h 95 + 0 + 0 + 0 
8 b 7 Selectfluor TFA rt 24 h 95 + 0 + 0 + 0 
9 a 7 NCS, Selectfluor acetonitrile rt 24 h 62 + 0 + 15 + 20 
10 a 7 NCS, Selectfluor acetonitrile 80 °C 1 h 62 + 0 + 15 + 20 
11 7 NCS, Selectfluor TFA rt 24 h 36 + 26 + 11 + 16 
12 7 NCS, Selectfluor TFA 80 °C 1 h 36 + 26 + 11 + 16 
13 b 7 NCS, Selectfluor TFA 80 °C 1 h 36 + 25 + 11 + 17 
a catalytic amount of TFA; b 2 equiv. of TEMPO. 
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The structures of the newly synthesized compounds (17, 20, and 21) were established through 
1H- and 13C-NMR measurements. The configuration of the newly formed chiral center at C-10 in the 
13α-epimer (17) was deduced from the comparison of the 1H-NMR spectra of the two 
10-fluoro-13-epimeric compounds (9 [16] and 17). The multiplets of 1-H appeared with similar 
shapes and coupling constants in the two spectra, suggesting the same configuration (10β-F) of the 
new chiral center. It can be stated that owing to the long distance of the angular methyl group from 
ring A, the configuration of C-13 does not influence that of C-10. 
2.2. Aromatase Inhibition Studies 
Literature reveals that type I inhibitors for aromatase might be designed not only based on the 
substrate of the enzyme, but also on its product estrone (7) [1]. It was published that 2-halogenated 
(with F, Cl, and Br) estrone derivatives display high binding affinity to the enzyme with Ki values in 
the submicromolar or micromolar range [25]. The 17-Oxo analogs seemed to be more potent than the 
corresponding 17β-hydroxy compounds. It was stated that the presence of the 17-carbonyl function 
is necessary in the binding of estrogens to the active site of the aromatase enzyme [7,26–28]. The 
4-halogenated derivatives proved to be less potent than their 2-substituted counterparts. We 
reported recently that 2-, 4- or 2,4-bis-halogenated (Cl, Br, I) 13α-estrones and their 17-deoxy 
derivatives possess weak aromatase inhibitory action [29]. It was demonstrated that the 
conformational differences of 13-epimeric estrones 7 and 12 resulting from the inversion of 
configuration at C-13 led to different binding affinities of 13-epimers to the aromatase. The 
inhibitory data obtained earlier for ring A halogenated 13β- and 13α-estrones indicate that the 
nature of the C-17 functional group, the conformation of the sterane core, and the substitution 
pattern of ring A might significantly influence the inhibitory behavior.  
Here, we expected that the binding affinity of estrane-based potential inhibitors might be 
improved by transforming the aromatic ring A into the 1,4-dien-3-one moiety. This structural 
element relates to that of the substrate of the enzyme. There exist numerous literature reports on the 
development of substrate-like aromatase inhibitors bearing the androsta-1,4-dien-3-one structure 
[1]. However, only a few estra-1,4-dien-3-ones have been evaluated for their inhibitory properties 
[30–33]. Our idea was to develop type I potential aromatase inhibitors, which possess the key 
structural elements, such as the 1,4-dien-3-one in ring A and the 17-oxo function, but instead of the 
C-19 methyl group, a promising fluorine substituent. We expected that the small, but highly 
electronegative fluorine will markedly improve the binding properties of the compounds. These 
structural modifications on the 13α-estrane core could result in compounds acting selectively 
without estrogenic behavior. The investigation of in vitro aromatase inhibitory action of test and 
reference compounds was performed by a radiosubstrate incubation method established previously 
[29]. Our experiments reveal that the 13β-epimer (9) was highly potent with an IC50 value in the 
submicromolar range (Table 3). This compound exerted similar potency to reference compounds 
androst-4-ene-3,17-dione and androst-1,4-diene-3,17-dione. Unfortunately, the 13α-epimer (17) 
displayed only a very weak inhibitory action. Concerning the 17-deoxy compounds (20 and 21), the 
same tendency was observed, namely that only the 13β derivative (20) inhibited the aromatase 
enzyme. The difference of one order of magnitude in the IC50 values of 17-oxo (9) and its 17-deoxy 
counterpart (20) indicates that the presence of a 17-keto function is advantageous in binding of the 
inhibitor. The 13α-epimer of the 17-deoxy derivative (21) displayed similar affinity to the enzyme to 
that of its 17-oxo (17) counterpart. The 10-chloro-13β-derivative (22) proved to be a potent inhibitor 
with an IC50 value in the low micromolar range, however literature reveals estrogenic activity for 
compound 22 comparable to that of estrone [34]. Figure 2 shows the concentration-dependent 
inhibitory action of the potent compounds (9, 20 and 22) and that of the reference compound 
androst-1,4-diene-3,17-dione. The results obtained for 10-fluoro- and 10-chloro-13β compounds (9 
and 22) suggest that introduction of a more electronegative but smaller halogen onto C-10 is more 
advantageous.  
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Table 3. In vitro inhibition of aromatase activities by the test compounds and reference agents. 
Relative conversions (Rel. conv., control incubation with no inhibition is 100%) measured in the 
presence of 10 µM concentration of the compound tested. Mean ± SD, n = 3. IC50: inhibitor 
concentration decreasing the enzyme activity to 50%. SD: standard deviation. 
Compound Structure 
IC50 ± SD (µM) or  
Rel. conv. ± SD (%) 
9 
H
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O
H
F
O
 
IC50 = 0.49 ± 0.07 
20 
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H
F
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93 ± 11 
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IC50 = 0.26 ± 0.06 
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Figure 2. The concentration-dependent inhibitory action of the three potent compounds (9, 20 and 
22) and that of the reference compound androst-1,4-diene-3,17-dione. 
2.3. Molecular Docking Studies 
Having obtained an atomic level explanation concerning biological activity, computational 
simulations were carried on for all 5 ligands (9, 17, 20, 21, and 22) and the original 
androst-1,4-diene-3,17-dione molecule. Docking studies were performed by the Glide program [35–
37], where the concerned receptor model was based on X-ray crystal structure selected from the PDB 
database (pdb code:3S79, [38]). The accuracy of the chosen protocol was verified by a redocking 
calculation, where a ligand from the X-ray complex was taken away and redocked into the original 
binding pocket. The XP docking protocol could reproduce the original binding pose with 0.1893 Å 
RMSD accuracy, but according to the Glide-score value, it was ranked in second position. Further 
information about the fitted X-ray and redocked ligand structures is presented in the supporting 
information (see Figure S1). Considering the Emodel scoring values, we had proper binding 
geometry and the original crystal position was ranked in the top position. This is in line with the 
theoretical background of the two scoring functions [37], as the Glide score was developed for large 
and diverse molecules set to maximize separation of compounds with strong or weak binding 
affinity. On the other hand, the Emodel value was developed for comparing analogous conformers, 
and much less for comparing chemically distinct species. Taking into account that our ligand set 
consists of very similar molecules, ligand poses with the best Emodel values were selected as 
docking results in each case and the corresponding scoring values are summarized in Table 4. 
Table 4. The scoring values for compounds 9, 17, and 20–22. 
Compound Emodel Score Glide Score 
22 −80.929 −4.973 
9 −79.415 −4.626 
20 −72.055 −4.192 
21 −64.406 −3.642 
17 −61.448 −3.642 
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We can see that the Glide score could not separate characteristically active and inactive 
compounds, but the 13-epimer pairs (9 vs. 17 and 20 vs. 21) were always distinguished with proper 
binding preference order. Concerning the Emodel scores, the binding preference provided suitable 
separation of biologically active and inactive molecules as active molecules had better, i.e., more 
negative, scoring values. We would like to note that Androst-1,4-diene-3,17-done was also docked 
for reference reason, and it had −81.343 and −5.114 Emodel and Glide score values, respectively. This 
is in line with experiments, since this compound showed good biological activity (see Table 3). 
Focusing now on the binding geometry of the ligands, we presented the docking pose of ligand 
22 with the best Emodel score in Figure 3(a). It represents clearly the possible interaction with the 
heme group with the Fe as well as the H-bond between ligand 22 and the Met374 residue. Other 
parts of the ligands fitted into the binding pocket did not provide any characteristic interactions 
(e.g., H-bond or π–π stacking) with the surrounding amino acids. Additionally, the poses of 
biologically active and inactive ligands are also presented in Figure 3(b) and (c), respectively, where 
the original ligand androstenedione geometry in the X-ray structure was also represented by purple 
wire. It demonstrated clearly that in the non-active cases (compounds 17 and 21) the backbone had 
notable distortion, while biologically active molecules (9, 20 and 22) provided almost exactly the 
same sterane skeleton arrangement when compared to the original X-ray geometry. The distortion of 
the sterane skeleton in the non-active cases (compounds 17 and 21) was the consequence of inversion 
of C-13, which had an effect on the conformation of ring D as well. This certainly weakened the 
interaction between the 17-oxo function of ligand 22 and the Met374 amino acid, which was pointed 
out previously in the literature to be an important interaction [38]. However, we believe that this 
interaction is not the only important factor in the binding efficiency of the ligand, as in the case of 
compound 20, which was found to be biologically active with the 17-oxo function completely 
missing. Moreover, compound 20 performed better concerning both biological activity and chemical 
binding than compound 17, which bears the 17-oxo group. 
 
(a) 
  
(b) (c) 
Figure 3. (a) The binding pose of ligand 22 with the best Emodel score. Distances are presented in Å. 
(b) The best binding pose of the biologically active ligands (9, 20, and 22) with the original X-ray 
ligand (molecule with purple line) pose. (c) The best binding pose of the biologically inactive ligands 
(17 and 21) with the original X-ray ligand (molecule with purple line) pose. 
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It is worth mentioning that the docking calculations of 17-deoxy compound 21 provided a 
geometry where the orientation of the sterane skeleton was turned around, and the oxygen on ring 
A tried to play the role of the ring D oxygen in the interaction with the Met379. In this case, however, 
neither the Glide score nor the Emodel score indicated strong interaction. 
From a theoretical point of view, these results put into focus two, not necessarily exclusive, 
explanations. On the one hand, there should be an interaction between the heme and the methyl 
groups and/or halogen groups in positions 13 and 10. This interaction, however, is weakened by the 
inversion at C-13. On the other hand, the inversion changed the hydrophobic interaction of the 
ligand in the binding pocket as well, which could also lead to a weaker ligand binding. Moreover, 
these effects obviously overrule the loss of the interaction with the Met379 residue. This became 
clear when we compared the scoring of ligand 20 to the results of ligand 17. 
3. Materials and Methods 
3.1. Chemical Synthesis 
3.1.1. General 
Melting points (Mp) were determined with a Kofler hot-stage apparatus and are uncorrected. 
Elemental analyses were performed with a Perkin-Elmer CHN analyzer model 2400. Thin-layer 
chromatography: silica gel 60 F254; layer thickness 0.2 mm (Merck, Darmstadt, Germany); eluents: a: 
40% ethyl acetate/60% hexanes, b: 25% ethyl acetate/75% hexanes, detection with I2 or UV (365 nm) 
after spraying with 5 % phosphomolybdic acid in 50 % aqueous phosphoric acid and heating at 100–
120 °C for 10 min. Flash chromatography: silica gel 60, 40–63 µm (Merck). 1H-NMR spectra were 
recorded in DMSO-d6, CDCl3 solution with a Bruker DRX-500 instrument at 500 MHz, with Me4Si as 
internal standard. 13C NMR spectra were recorded with the same instrument at 125 MHz under the 
same conditions. Mass spectrometry: Full scan mass spectra of the compounds were acquired in the 
range of 50 to 1000 m/z with a Finnigan TSQ-7000 triple quadrupole mass spectrometer 
(Finnigan-MAT, San Jose, CA) equipped with a equipped with a Finnigan electrospray ionization 
source. Analyses were performed in positive ion mode using flow injection mass spectrometry with 
a mobile phase of 50 % aqueous acetonitrile containing 0.1 v/v % formic acid. The flow rate was 0.3 
ml/min. Five µl aliquot of the samples were loaded into the flow. The ESI capillary was adjusted to 
4.5 kV and N2 was used as a nebulizer gas.  
3.1.2. Synthesis of 10β-Fluoroestra-1,4-dien-3-one (9) or 10β-Fluoro-13α-estra-1,4-dien-3-one (17) in 
acetonitrile 
Estrone (7) (135 mg, 0.5 mmol) or 13α-estrone (12) (135 mg, 0.5 mmol) was dissolved in 
acetonitrile (5 ml) and Selectfluor (2) (195 mg, 0.55 mmol) was added. The mixture was stirred at rt 
for 24 h or at 80 °C for 1 h, the solvent was then evaporated off, and the crude product (9 or 17) was 
purified by flash chromatography with 2% ethyl acetate/98% dichloromethane as eluent. 
Compound 9 was obtained as a white solid (137 mg, 95% or 140 mg, 97%, Mp.: 104–102 °C, Rf = 
0.42a). Compound 9 is identical with compound described in the literature [15]. 1H-NMR (DMSO-d6) 
δ ppm 0.86 (s, 3H, 18-H3); 2.41 and 2.53 (2 × m, 2 × 1H, 6-H2); 6.10 (s, 1H, 4-H); 6.22 (d, 1H, J = 10.2 Hz, 
2-H); 7.27 (dd, 1H, J = 10.2 Hz, J = 7.4 Hz, 1-H). 
Compound 17 was obtained as a white solid (140 mg, 97% or 141 mg, 98%, Mp.: 142–144 °C, Rf = 
0.23b). Anal. Calcd. for C18H21FO2: C, 74.97; H, 7.34. Found: C, 74.85; H, 7.39. 1H-NMR (CDCl3) δ ppm 
0.99 (s, 3H, 18-H3); 1.14–2.68 (15H); 6.04 (s, 1H, 4-H); 6.22 (d, 1H, J=10.2 Hz, 2-H); 7.06 (dd, 1H, J = 10.2 
Hz, J = 7.7 Hz, 1-H). 13C-NMR (CDCl3) δ ppm 21.6; 23.6; 24.9 (C-18); 31.1; 31.5; 33.4; 34.0; 37.4; 49.1; 
49.8 (C-13); 51.7 (d, J = 24.0 Hz, C-9); 88.9 (d, J = 167.9 Hz, C-10); 123.7 (d, J = 5.0 Hz, C-4); 129.7 (d, J = 
8.7 Hz, C-2); 144.7 (d, J = 23.8 Hz, C-1); 159.8 (d, J = 18.9 Hz, C-5); 184.8 (C-3); 220.7 (C-17). MS m/z (%): 
289 (100, [M + H]+). 
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3.1.3. Synthesis of 10β-Fluoroestra-1,4-dien-3-one (9) or 10β-Fluoro-13α-estra-1,4-dien-3-one (17) in 
methanol 
Estrone (7) (135 mg, 0.5 mmol) or 13α-estrone (12) (135 mg, 0.5 mmol) was dissolved in 
methanol (5 ml) and Selectfluor (2) (195 mg, 0.55 mmol) was added. The mixture was stirred at rt for 
24 h or at 80 °C for 1 h, the solvent was then evaporated off, and the crude product (9 or 17) was 
purified by flash chromatography with 2% ethyl acetate/98% dichloromethane as eluent. 
Starting from compound 7, first eluted the mixture of 15:16 = 1:1.5 and was obtained as an oil 
(23 mg, 16% or 22 mg, 15%). Then eluted compound 9 and was obtained as a white solid (110 mg, 
76% or 112 mg, 78%). Compounds 15 and 16 have not been separated. The relevant signals selected 
from the 1H-NMR spectrum of the mixture for compound 16 (DMSO-d6) δ ppm: 0.82 (s, 3H, 18-H3); 
6.71 (t, 1H, J = 8.8 Hz, 2-H); 6.88 (d, 1H, J = 8.8 Hz, 1-H); 9.43 (s, 1H, OH). The relevant signals selected 
from the 1H-NMR spectrum of the mixture for compound 15 (DMSO-d6) δ ppm: 0.82 (s, 3H, 18-H3); 
6.61 (d, 1H, J = 9.3 Hz, 4-H); 6.97 (d, 1H, J = 13.2 Hz, 1-H); 9.47 (s, 1H, OH). Then eluted compound 9 
and was obtained as a white solid.  
Starting from compound 12, first eluted the mixture of 18:19 = 1:1.5 and was obtained as an oil 
(17 mg, 12% or 19 mg, 13%). Compounds 18 and 19 have not been separated. The relevant signals 
selected from the 1H-NMR spectrum of the mixture for compound 18 (DMSO-d6) δ ppm: 0.96 (s, 3H, 
18-H3); 6.58 (d, 1H, J = 9.2 Hz, 4-H); 6.97 (d, 1H, J = 13.9 Hz, 1-H); 9.47 (s, 1H, OH). The relevant 
signals selected from the 1H-NMR spectrum of the mixture for compound 19 (DMSO-d6) δ ppm: 0.96 
(s, 3H, 18-H3); 6.69 (t, 1H, J = 8.8 Hz, 2-H); 6.88 (d, 1H, J = 8.8 Hz, 1-H); 9.42 (s, 1H, OH). Then eluted 
compound 17 and was obtained as a white solid (102 mg, 71% or 105 mg, 73%).  
3.1.4. General Procedure for the Fluorination with Selectfluor in Acetonitrile or in Methanol by 
Adding TEMPO 
Estrone (7) (135 mg, 0.5 mmol) or 13α-estrone (12) (135 mg, 0.5 mmol) was dissolved in 
acetonitrile (5 ml) or in methanol (5 ml), Selectfluor (2) (195 mg, 0.55 mmol) and TEMPO (156 mg, 1.0 
mmol) were added. The mixture was stirred at rt for 24 h, and the reaction was monitored by TLCa. 
The crude products were purified by flash chromatography with 2% ethyl acetate/98% 
dichloromethane as eluent. Compound 9 or 17 was obtained as a white solid only in traces (2–4%).  
3.1.5. Synthesis of 10β-Fluoro-17-deoxyestra-1,4-dien-3-one (20) or 
10β-Fluoro-17-deoxy-13α-estra-1,4-dien-3-one (21) 
17-Deoxy-estrone (13) (128 mg, 0.50 mmol) or 17-deoxy-13α-estrone (14) (128 mg, 0.50 mmol) 
was dissolved in acetonitrile (5 mL) and Selectfluor (2) (195 mg, 0.55 mmol) was added. The mixture 
was stirred at rt for 24 h, the solvent was then evaporated off, and the crude product was purified by 
flash chromatography with 5% ethyl acetate/95% hexane. 
Compound 20 was obtained as an oil (129 mg, 94%, Rf = 0.72b). Anal. Calcd. for C18H23FO: C, 
78.80; H, 8.45. Found: C, 78.71; H, 8.37. 1H-NMR (CDCl3) δ ppm 0.80 (s, 3H, 18-H3); 2.41 and 2.67 (2 × 
m, 2 × 1H, 6-H2); 6.03 (s, 1H, 4-H); 6.23 (d, 1H, J = 9.8 Hz, 2-H); 7.10 (t, 1H, J = 9.8 Hz, 1-H). 13C-NMR 
(CDCl3) δ ppm 17.3 (C-18); 20.3; 23.1; 25.7; 32.0; 33.5; 36.1; 38.1; 40.1; 40.9 (C-13); 53.2; 54.5 (d, J = 24.8 
Hz, C-9); 88.9 (d, J = 167.8 Hz, C-10); 123.4 (d, J = 4.6 Hz); 129.2 (d, J = 8.5 Hz); 145.7 (d, J = 14.5 Hz, 
C-1); 161.0 (d, J = 18.6 Hz, C-5); 185.3 (C-3). MS m/z (%): 275 (100, [M + H]+). 
Compound 21 was obtained as an oil (126 mg, 92%, Rf = 0.67b). Anal. Calcd. for C18H23FO: C, 
78.80; H, 8.45. Found: C, 78.73; H, 8.35. 1H-NMR (CDCl3) δ ppm 0.89 (s, 3H, 18-H3); 2.39 and 2.63 (2 × 
m, 2 × 1H, 6-H2); 6.02 (s, 1H, 4-H); 6.22 (d, 1H, J = 10.3 Hz, 2-H); 7.11 (dd, 1H, J = 10.3 Hz, J = 7.5 Hz, 
1-H). 13C-NMR (CDCl3) δ ppm 21.0; 22.2; 28.7; 29.7 (C-18); 31.9; 33.6; 34.3; 34.8; 37.3; 41.6 (C-13); 51.9; 
52.6 (d, J = 24.1 Hz, C-9); 88.9 (d, J = 161.1 Hz, C-10); 123.4 (d, J = 4.7 Hz, C-4); 129.5 (d, J = 8.6 Hz, C-2); 
145.2 (d, J = 14.4 Hz, C-1); 160.8 (d, J = 19.2 Hz, C-5); 185.1 (C-3). MS m/z (%): 275 (100, [M + H]+). 
3.1.6. Fluorination of estrone (7) with Selectfluor in TFA 
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Estrone (7) (135 mg, 0.5 mmol) was dissolved in TFA (3 mL) and Selectfluor (2) (195 mg, 0.55 
mmol) was added. The mixture was stirred at rt for 24 h or at 80 °C for 1 h, then cooled to rt, poured 
onto 100 ml water and extracted with diethyl ether. The organic phase was dried over anhydrous 
sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography 
with 2% ethyl acetate/98% dichloromethane as eluent. Compound 9 was obtained as a white solid 
(138 mg, 96% or 137 mg, 95%). 
3.1.7. Fluorination of Estrone (7) with Selectfluor in TFA by Adding TEMPO 
Estrone (7) (135 mg, 0.5 mmol) was dissolved in TFA (3 mL), Selectfluor (2) (195 mg, 0.55 mmol) 
and TEMPO (156 mg, 1.0 mmol) were added. The mixture was stirred at rt for 24 h, then poured onto 
100 ml water and extracted with diethyl ether. The organic phase was dried over anhydrous sodium 
sulfate, filtered and evaporated. The crude product was purified by flash chromatography with 2% 
ethyl acetate/98% dichloromethane as eluent. Compound 9 was obtained as a white solid (137 mg, 
95%). 
3.1.8. Chlorination of Estrone (7) with NCS in Acetonitrile  
Estrone (7) (135 mg, 0.5 mmol) was dissolved in acetonitrile (5 mL), trifluoroacetic acid (0.005 
mL) and NCS (74 mg, 0.55 mmol) were added. The mixture was stirred at rt for 24 h or at 80 °C for 1 
h, the solvent was then evaporated off, and the crude product was purified by flash chromatography 
with 10% ethyl acetate/90% hexane. First eluted compound 24 (37 mg, 24%), which was obtained as a 
white solid. Mp.: 181–183 °C, [34]: 272–274 °C, Rf: 0.46a. Continued elution yielded the mixture of 
compounds 24 (32 mg, 21%) and 23 (26 mg, 17%). Finally eluted 23 (20 mg, 13%), which was 
obtained as a white solid. Mp.: 203–205 °C, [35]: 262–264 °C, Rf: 0.42a. Compounds 23 and 24 are 
identical with those described in [28].  
3.1.9. Chlorination of Estrone (7) with NCS in TFA 
Estrone (7) (135 mg, 0.5 mmol) was dissolved in TFA (3 mL) and NCS (74 mg, 0.55 mmol) was 
added. The mixture was stirred at rt for 24 h or at 80 °C for 1 h, and then cooled to rt, poured onto 
100 mL water and extracted with diethyl ether. The organic phase was dried over anhydrous sodium 
sulfate, filtered and evaporated. The crude product was purified by flash chromatography with 10% 
ethyl acetate/90% hexane. First eluted 24 (20 mg, 13%). Continued elution yielded the mixture of 24 
(11 mg, 7%) and 23 (9 mg, 5.6%). Then eluted 23 (7 mg, 4.4%). Finally eluted 22 (84 mg, 55%). 
Compound 22 was obtained as a white solid. 1H-NMR (CDCl3) δ ppm 0.98 (s, 3H, 18-H3); 6.09 (s, 
1H, 4-H); 6.20 (d, 1H, J = 10.1 Hz, 2-H); 7.12 (d, 1H, J = 10.1 Hz, 1-H). 13C-NMR (CDCl3) δ ppm 13.7 
(C-18); 21.9; 22.4; 30.6; 31.4; 32.0; 35.5; 35.6; 47.6 (C-13); 49.7; 53.2; 67.5 (C-10); 124.1; 126.9; 147.4 (C-1); 
160.4 (C-5); 184.9 (C-3); 219.7 (C-17). Compound 22 is identical with compound described in the 
literature [34]. 
3.1.10. Chlorination of estrone (7) with NCS in TFA by adding TEMPO 
Estrone (7) (135 mg, 0.5 mmol) was dissolved in TFA (3 mL), NCS (74 mg, 0.55 mmol) and 
TEMPO (156 mg, 1.0 mmol) were added. The mixture was stirred at 80 °C for 1 h, and then cooled to 
rt, poured onto 100 mL water and extracted with diethyl ether. The organic phase was dried over 
anhydrous sodium sulfate, filtered and evaporated. The crude product was purified by flash 
chromatography with 10% ethyl acetate/90% hexane. First eluted 24 (21 mg, 14%). Continued elution 
yielded the mixture of 24 (11 mg, 7%) and 23 (10 mg, 7.0%). Then eluted 23 (6 mg, 4.0%). Finally 
eluted 22 (82 mg, 54%). 
3.1.11. Fluorination and Chlorination of Estrone (7) with Selectfluor and NCS in Acetonitrile  
Estrone (7) (135 mg, 0.5 mmol) was dissolved in acetonitrile (5 mL), Selectfluor (2) (195 mg, 0.55 
mmol), NCS (74 mg, 0.55 mmol) and trifluoroacetic acid (0.005 mL) were added. The mixture was 
stirred at rt for 24 h or at 80 °C for 1 h, the solvent was then evaporated off, and the crude product 
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was purified by flash chromatography with 10% ethyl acetate/90% hexane. First eluted 24 (15 mg, 
9.8%). Continued elution yielded the mixture of 24 (14 mg, 9.2%) and 23 (10 mg, 6.6%). Then eluted 
23 (12 mg, 8.4%). Finally eluted 9 (94 mg, 62%). 
3.1.10. Fluorination and Chlorination of Estrone (7) with Selectfluor and NCS in TFA  
Estrone (7) (135 mg, 0.5 mmol) was dissolved in TFA (3 mL), Selectfluor (2) (195 mg, 0.55 mmol) 
and NCS (74 mg, 0.55 mmol) were added. The mixture was stirred at 80 °C for 1 h, and then cooled 
to rt, poured onto 100 mL water and extracted with diethyl ether. The organic phase was dried over 
anhydrous sodium sulfate, filtered and evaporated. The crude product was purified by flash 
chromatography with 10% ethyl acetate/90% hexane. First eluted 24 (14 mg, 9.2%). Continued 
elution yielded the mixture of 24 (10 mg, 6.8%) and 23 (9 mg, 5.9%). Then eluted 23 (8 mg, 5.1%). 
Finally eluted separately 22 (40 mg, 26%) 9 (55 mg, 36%). 
3.1.12. Fluorination and Chlorination of Estrone (7) with Selectfluor and NCS in TFA by Adding 
TEMPO 
Estrone (7) (135 mg, 0.5 mmol) was dissolved in TFA (3 mL), Selectfluor (2) (195 mg, 0.55 mmol), 
NCS (74 mg, 0.55 mmol) and TEMPO (156 mg, 1.0 mmol) were added. The mixture was stirred at 80 
°C for 1 h, and then cooled to rt, poured onto 100 mL water and extracted with diethyl ether. The 
organic phase was dried over anhydrous sodium sulfate, filtered and evaporated. The crude product 
was purified by flash chromatography as it is described in Section 3.1.11. 
3.2. Aromatase Inhibition 
3.2.1. General 
[4(N)-14C]Testosterone was obtained from American Radiolabeled Chemicals, St. Louis, MO, 
USA). Chemicals and solvents of analytical grade purity were purchased from Sigma (St. Louis, MO, 
USA), from Fluka (Buchs, Switzerland) or from Merck (Darmstadt, Germany). 
3.2.2. Preparation of Enzyme Sources 
Human term placentae were collected immediately after delivery and stored frozen at −80 °C. 
Tissue specimens were homogenized with an Ultra-Turrax in 0.1 M HEPES buffer solution (pH = 7.3) 
containing 1 mM EDTA and 1 mM dithiotreitol, and microsomas were obtained with fractionated 
centrifugation. Application of the human tissue was approved by the institutional Human 
Investigation Review Board.  
3.2.3. Incubation Procedures 
The microsoma suspension was incubated with 1.0 M [4(N)-14C]testosterone substrate in the 
presence of 0.1 mM NADPH cofactor excess. Enzymatic incubations were carried out in the HEPES 
buffer medium at a final volume of 200 µL. The substrate was added to the incubate in 20 L of a 25 
v/v% propylene glycol in HEPES buffer solution, whereas test compounds were applied in 10 L of 
dimethyl sulfoxide solution. Incubations were performed at 37 °C and lasted for 40 min. Enzymatic 
reaction was terminated by cooling and the addition of organic solvents of the subsequent extraction 
procedure. Control samples with no inhibitor and blank samples were incubated simultaneously. 
The incubation mixture was extracted with toluene, then the toluene phase was drained and washed 
with HEPES buffer. Aromatase products containing phenolic hydroxy group were extracted with 1.2 
M sodium hydroxide solution from the toluene extract and radioactivity of the alkaline phase was 
measured in liquid scintillation counting. 
3.2.4. Inhibition Studies 
In the general procedure, test compounds were applied at 10 M final concentration in the 
incubate. Relative conversions compared to non-inhibited controls (100%) were determined. The 
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assays were performed in triplicate, and the mean value and the standard deviation (SD) were 
calculated. IC50 values (the inhibitor concentration that decreases the enzyme activity to 50%) were 
determined for the most effective test compounds and for reference compounds. In these cases, 
conversions were measured at 10–15 different concentrations in the appropriate interval between 
0.001–50 M. IC50 results were calculated by using unweighted iterative least squares logistic curve 
fitting by means of the “absolute IC50 calculation“ function of the GraphPad Prism 4.0 software 
(GraphPad Software, Inc., San Diego, CA, USA). 
3.3. Computational Simulations 
Docking studies were performed with the Glide [33–35] program from the Schrodinger suits 
using the XP protocol. Docking grid generation was based on X-ray crystal structure as it was 
deposited into the Protein Database (pdb code: 3S79) and refined by the Protein Preparation Wizard. 
During the XP docking calculations, enhanced sampling was selected and the energy window for 
ring sampling was also increased to 100 kcal/mol and the number of final outputs per ligand was 
enlarged to 10. All figures were prepared with the Maestro program [35] which is the GUI part of the 
Schrödinger program package. 
4. Conclusions 
In conclusion, fluorinations of 13-epimeric estrones (7 and 12) and their 17-deoxy counterparts 
(13 and 14) with Selectfluor (2) in acetonitrile furnished exclusively the corresponding 10-fluoro 
derivatives (9, 17, 20, and 21). Mechanistic studies suggest that reactions in acetonitrile occur via 
SET, while halogenations in TFA follow a different mechanism. The simultaneous application of the 
two halogenating agents (Selectfluor and NCS) in TFA results in 10-halogenated compounds 9 and 
22 as the main products at a ratio of about 1.3:1.0. The results obtained from the aromatase assay 
suggest that in estrane-based aromatase inhibitors, the presence of the small, β-oriented halogen at 
C-10 and the 1,4-diene-3,17-dione moiety are advantageous and might lead to potent derivatives 
with submicromolar inhibitory potential. Docking calculations reinforced that besides the 
well-known Met374 H-bond connection, the stereocenter in the 13 position has an important role in 
the binding affinity. Our results might contribute not only to the research field of type I steroidal 
inhibitors of aromatase, but also to the development of biologically active compounds bearing 
substituted phenol moieties, by improving their biological potency via halogenations. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1: Synthetic procedures, 
characterization data for the synthesized compounds, aromatase inhibition method and computational 
simulation methods. 
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